Bladder cancer’s high recurrence rate and lifelong monitoring requirements make it one of the most expensive cancers to manage globally. Hong Kong-based precision diagnostics company Codex Genetics recently announced an exclusive collaboration with Pacific Edge to bring non-invasive genomic urine tests for bladder cancer detection and monitoring to local hospitals and clinics.
Key Points
- The partnership provides Hong Kong clinicians access to Cxbladder’s suite of tests—Cxbladder Detect, Monitor, and Triage—which use genomic biomarker analysis combined with clinical algorithms for bladder cancer risk stratification and surveillance.
- Cxbladder Triage was included in the American Urological Association’s Microhematuria Guideline in February 2025, supported by Grade A evidence from the STRATA randomized controlled trial. The guideline endorses urine-based biomarkers to reduce reliance on cystoscopy procedures.
- Bladder cancer ranks as the ninth most common cancer worldwide. The tests aim to reduce unnecessary invasive procedures while providing earlier insights in patient care pathways.
This partnership aims to provide Hong Kong healthcare providers with non-invasive alternatives for bladder cancer detection and monitoring, potentially reducing the need for cystoscopy procedures in appropriate patients.
The Data
- According to the company, the Cxbladder tests have been used in over 100,000 patients globally and are supported by more than 25 peer-reviewed clinical studies. These tests demonstrate high sensitivity (accurately detecting cancer when present) and high negative predictive value (reliably ruling out cancer).
- Cxbladder Triage was included in updated clinical guidelines issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU).
- Bladder cancer is the ninth most common cancer worldwide.
Industry Context
Our collaboration with Cxbladder reflects Codex’s continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia.
Dr. Aldrin Yim, co-founder of Codex Genetics
The recently announced partnership addresses bladder cancer’s significant clinical and economic burden, driven primarily by high recurrence rates requiring lifelong patient monitoring. The Cxbladder suite offers three distinct tests designed for different clinical scenarios: detection, ongoing monitoring, and triage for patients with microhematuria. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to provide actionable insights.
